Transport characteristics of ribavirin in human erythrocytes were evaluated using rightside-out membrane vesicles (ROVs) prepared from fresh blood, and compared with those in intact erythrocytes. 
Introduction
Ribavirin (1--D-ribofuranosyl-1,2,4-triazole-3-carboxamide), a purine nucleoside analogue having a broad antiviral spectrum, is active in vitro and in vivo against a variety of DNA and RNA viruses. A combination of oral ribavirin with subcutaneous peginterferon -2b or peginterferon -2a is now a standard therapy in treating patients with chronic intractable hepatitis C, particularly with hepatitis C of genotype 1b and high viral titers. In this combination therapy, however, ribavirin-specific red blood cell disorders such as erythrocytopenia and decreases in hematocrit and hemoglobin levels are common and severe enough to require dose reduction in approximately 7 15% of patients 1, 2) . It has been shown that ribavirin is taken up by human erythrocytes and is phosphorylated to ribavirin triphosphate 3, 4) . Because dephosphorylating enzymes such as alkaline phosphatase are lacking in human erythrocytes, phospholylated metabolites of ribavirin highly accumulates in the cells 4, 5) . Though the precise mechanisms underlying ribavirin-induced erythrocytopenia are still unknown, the first step of the hematological toxicity should be the transport of ribavirin into the erythrocytes.
So far, only a limited study on the transport of ribavirin in human erythrocytes has been reported. Jarvis et al. 6) examined ribavirin uptake by using washed, intact erythrocytes and inhibitor oil-stop methods.
The uptake of ribavirin was saturable with a Km value of 0.44 mM, was inhibited by adenosine and S-(4-nitrobenzyl)-6-thioinosine (NBMPR), and was transstimulated by uridine. Based on these results, they concluded that ribavirin is taken up by human erythrocytes by NBMPR-sensitive nucleoside transporter (equilibrative nucleoside transporter 1; ENT1).
However, information concerning ribavirin transport in human erythrocytes is still lacking. In addition, as far as we know, there is no study that has examined ribavirin transport at the erythrocyte membrane level using membrane vesicles. These backgrounds prompted us to examine uridine, a typical substrate of ENT1, and ribavirin transport using human erythrocyte membrane vesicles.
During the above mentioned studies, we have noticed that uridine can be transported by ENT1 at icecold temperatures. In other words, ENT1 is functioning at ice-cold temperatures near 0 . Surprisingly, even overshoot uptake (uphill transport) of uridine was observed at ice-cold temperatures under certain conditions 7) . These studies have given us important information in order to estimate erythrocyte ENT1 function properly; addition of an ENT1 inhibitor such as NBMPR in the stop solution (the solution to stop the uptake reaction and to wash the membrane vesicles) is essential. In fact, about 90% of uridine taken up by erythrocyte membrane vesicles was effluxed during washing process using ice-cold stop solution without NBMPR, and therefore it was impossible to evaluate transport characteristics of uridine at the membrane level 7) . We suppose that this may be one of the reasons why no study on ribavirin transport in erythrocyte membrane vesicles has been reported so far.
In this study, we have evaluated the transport characteristics of ribavirin using rightside-out membrane vesicles (ROVs) prepared from human blood, and compared with those in intact erythrocytes. In addition, the interaction of ribavirin with efflux transporters expressed in erythrocyte membranes such as multidrug resistance-associated protein (MRP) 4 was also examined. Our results suggest that ribavirin is transported by ENT1 across human erythrocyte membranes, and ATP-dependent efflux transporters would not be involved in ribavirin transport in erythrocytes. Louis, MO, USA). ACS II was purchased from Amersham Pharmacia Biotech (Buckinghamshire, UK). All other chemicals used for the experiments were of the highest purity available.
Experimental Section

Materials
Preparation of washed, intact erythrocytes
Fresh blood was collected into tubes containing EDTA from healthy volunteers after obtaining written informed consent. The study was approved by Ethics Committee of Hiroshima University. Erythrocytes from 5 ml of fresh blood were washed three times with 50 ml of buffer A (140 mM NaCl, 5 mM KCl, 20 mM Tris/HCl, 2 mM MgCl2, 0.1 mM EDTA, pH 7.4) by centrifugation (1,500 g, 10 min) at room temperature.
The supernatant was carefully aspirated off to remove the buffy coat and plasma.
Preparation of rightside-out human erythrocyte membrane vesicles (ROVs)
ROVs were prepared from human erythrocytes by the method described previously 7, 8) . Briefly, 5 ml of fresh blood was washed with 25 ml of buffer B (137 mM NaCl, 2.7 mM KCl, 10.6 mM Na2HPO4, 8.5 mM KH2PO4, 1 mM MgCl2, 100 M EGTA, pH 7.4) by centrifugation. Erythrocytes were lysed by incubation with 120 ml of lysis buffer (50-fold diluted buffer B) for 60 min on ice. The lysate was washed by centrifugation with buffer B, and the pellet was incubated with 20 ml of buffer B for 45 min at 37 . After centrifugation, the pellet was washed with buffer C (100 mM mannitol, 10 mM HEPES/Tris, pH 7.4) by centrifugation. The final pellet containing ROVs was stored at -80 until use.
Preparation of inside-out human erythrocyte membrane vesicles (IOVs)
IOVs were prepared from human erythrocytes by the method described previously 7, 9) . Briefly, erythrocytes from 5 ml of fresh blood were washed with 40 ml of 0.9% NaCl by centrifugation. The cell suspension in one volume of 51 mM sodium phosphate buffer (pH 8.0) was rapidly mixed with 8.5 volumes of ice-cold lysis buffer (5.1 mM sodium phosphate buffer, pH 8.0).
The lysate was stirred for 15 min on ice, and the unsealed ghosts were washed with 60 ml of ice-cold lysis buffer by centrifugation. To initiate vesiculation, the pelleted unsealed ghosts were mixed with two volumes of 0.51 mM sodium phosphate buffer (pH 9.7). After 1.5 hours incubation on ice followed by 30 min at 37 , the vesicles formed were pelleted by centrifugation and the pellet was dispersed by vigorous vortex mixing. The vesicles were washed with buffer C by centrifugation. The final pellet containing IOVs was suspended in 300 l of buffer C and stored at -80 until use. After incubation for 5 sec at 23 , uptake reaction was terminated by the inhibitor-oil stop method 7) .
Uptake study by erythrocytes
Uptake study by ROVs
The uptake of ribavirin by ROVs was measured by a rapid filtration technique, as described previously 7, 10) . 
Uptake studies by IOVs
The uptake of a substrate by IOVs was measured by a rapid filtration technique, as described previously 7, 11, 12) . Briefly, 3 mg protein/ml of IOVs was pre- Other processes were the same as for the uptake study with ROVs.
Analytical methods
After the uptake experiments, the uptake amount of [ 3 H]ribavirin, CDCF and MTX was measured by liquid scintillation counting, Hitachi fluorescence spectrophotometer F-3000 (Tokyo, Japan) (Ex 500 nm, Em 523 nm), and HPLC (304 nm), respectively, as described previously 7, 11, 12) . Protein concentrations were measured by the method of Bradford with bovine serum albumin as a standard 13) .
Statistical analysis
The data were expressed as the mean S.E.. This value was similar to that observed in uridine transport study 7) . NBMPR added in the stop solution inhibited the efflux in a concentration-dependent fashion.
Thus, as reported recently 7) , ENT1 is functioning at ice- be deviation from the linear range of the uptake rate, and the uptake values may be underestimated to some extent.
Concentration-dependence of ribavirin uptake by ROVs and erythrocytes
The concentration-dependence of ribavirin uptake by ROVs was examined. As shown in Fig. 2A, [ nmol/mg protein/sec, respectively. When these values were compared with those of [ 3 H]uridine uptake by ROVs, ribavirin transport was found to be low-affinity and high-capacity than uridine 7) . Similar to the uptake by ROVs, [ 3 H]ribavirin uptake by washed, intact erythrocytes showed saturation kinetics (Fig. 2B) , and the Km and Vmax values were calculated to be 1.0 mM and 76.3 pmol/mg protein/sec, respectively. Though the Vmax value could not be compared between these two experimental systems, Km value obtained in ROVs was higher (the apparent affinity was lower) than that in erythrocytes. EadieHofstee plots shown in the insets in Fig. 2A 
Effects of uridine and ENT1 inhibitors on ribavirin uptake by ROVs and erythrocytes
Jarvis et al. 6) examined ribavirin uptake by intact erythrocytes and suggested that ribavirin is taken up by human erythrocytes by NBMPR-sensitive nucleoside transporter (ENT1). Therefore, the effect of uridine, a typical substrate of ENT1, and NBMPR and dipyridamole, inhibitors of ENT1, were examined. As shown in Fig. 3A , the uptake of distributed in various tissues, including erythrocytes, liver, heart, spleen, kidneys, lungs, intestines, and brain 17) . We also confirmed the expression of ENT1
protein by Western blotting in ROVs that we have prepared 7) . On the other hand, there has been no report indicating the expression of CNT in erythrocyte membranes. In order to examine whether CNT is functionally expressed in human erythrocyte or not, we examined the effect of Na + gradient on [ 3 H]uridine uptake by ROVs. However, no effect of Na + gradient on the uptake was observed (data not shown), supporting that CNT is not expressed in human erythrocytes.
Recently, Endres et al. 18) examined the role of ENT1 in ribavirin uptake using wild-type and ENT1(-/-) mouse erythrocytes, and clearly showed that ENT1 is responsible for the uptake of ribavirin in mouse erythrocytes.
Taken together, the transporter involved in ribavirin uptake by human erythrocytes would be ENT1. are substrates of MRP4 and MRP5 23) . Therefore, the interaction of ribavirin with MRP4 and MRP5 was examined using IOVs. ATP-dependent uptake of MTX, which is predominantly mediated by MRP4, was significantly inhibited by ribavirin in a concentrationdependent manner (Fig. 6A) , though millimolar concentrations of ribavirin were needed for the inhibition.
Interaction of ribavirin with efflux transporters in human erythrocyte membranes
The uptake of MTX was also inhibited by uridine (data not shown). On the other hand, ATP-dependent uptake of CDCF, which is predominantly mediated by MRP5, was not significantly affected by ribavirin (Fig. 6B) . Therefore, ribavirin and uridine may inter- In conclusion, the role of ENT1 in ribavirin transport across human erythrocyte membranes was clearly shown at the membrane level. In addition, it was found that ATP-dependent efflux transporters would not be involved in ribavirin transport in erythrocytes. Thus, ENT1 should be a crucial transporter that determines ribavirin level in human erythrocytes and therefore ribavirin-induced erythrocytopenia.
